Although allowing patients in the control group of a clinical trial to switch onto the experimental treatment is a common occurrence in oncology drug trials, it can present significant challenges for the accurate interpretation of trial findings when a substantial number of patients switch treatments. The session start by defining the problem and will then look at the international regulatory landscape, emerging statistical methods, best practice guidelines ending with a look at the impact on participant information and management.
Chairperson: Kylie Sproston, Bellberry
- Clinical Research
- Date:May 12, 2016
- Time:1:30 pm